EGFR and non-small cell lung carcinoma: Apart from the potential bias introduced by data completeness during the earlier years, this increase probably reflects an enhanced awareness of the need for EGFR mutation testing in patients with advanced NSCLC before initiation of first-line therapy, as recommended in clinical practice guidelines published at that time [21,22], or to a wider availability of a validated test.